We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Stago Diagnostics Transforms Hemostasis with Innovations at AACC 2020 Virtual Event

By LabMedica International staff writers
Posted on 17 Dec 2020
Print article
Illustration
Illustration
Diagnostica Stago (Asnières-sur-Seine, France) transformed hemostasis with its innovations on display at the all virtual 2020 AACC Annual Scientific Meeting held on December 13-17.

The company demonstrated the STA Workcell Max, a transformative specimen processing platform designed to meet the rigorous requirements of efficient hemostasis testing. With a loading capacity of 300 specimens at a time, STA Workcell Max automatically loads and balances centrifuge buckets, and prepares platelet poor plasma by centrifuging specimens using hemostasis-specific criteria. By automating front-end specimen processing, rack preparation and specimen routing, the STA Workcell Max enables allocation of skilled laboratory technologists for other more complex, value-added tasks.

Attendees of the 2020 AACC Virtual Meeting Platform viewed the company’s STA Coag Expert data management platform powering the STA Workcell Max automation line, that transforms lab QC and patient results into robust, traceable, actionable clinical insights. STA Coag Expert delivers full traceability, from operator activity to reagent and consumable lot identification for each data point. Also included, are connectivity capabilities to auto-upload QC results into a real-time peer comparison program, MyExpertQC. Diagnostica Stago’s suite of digital services, including remote monitoring and proactive instrument alerts, further enhance the value of STA Coag Expert by reducing TAT and increasing system efficiency.


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Fixed Speed Tube Rocker
GTR-FS

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.